Executive Summary
This week's digest highlights: Preliminary evidence; confirm full-text methods and endpoints before changing practice. For caregivers of PMBT patients with anxiety, interventions like NeuroCARE that enhance coping and self-efficacy can effectively reduce distress. Preliminary evidence; confirm full-text methods and endpoints before changing practice...
Owen briefs you on what matters in this week's digest.
Think chief-resident chalk talk: what matters, what changes practice, and where to spend your reading time.
Endovascular / Vascular
Comparison of Triple Antiplatelet (Aspirin, Clopidogrel, and Cilostazol) and Modified Dual Antiplatelet (Aspirin and Low-Dose Prasugrel) Therapy in Patients With High On-Treatment Platelet Reactivity Undergoing Stent-Assisted Coil Embolization for an Unruptured Intracranial Aneurysm: A Prospective Randomized Clinical Trial.
Research • Endovascular / Vascular • Neurosurgery • 2025-10-10
Preliminary evidence; confirm full-text methods and endpoints before changing practice.
Study snapshot
Design
Prospective, randomized clinical trial
Population
Patients with high on-treatment platelet reactivity undergoing stent-assisted coil embolization for unruptured intracranial aneurysm
Intervention
Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol)
Comparator
Modified dual antiplatelet therapy (aspirin, low-dose prasugrel)
Primary outcome
All-bleeding-events during 90-day follow-up
Why it matters
Before this study, the optimal antiplatelet regimen for patients with high on-treatment platelet reactivity (HTPR) undergoing stent-assisted coiling was unclear. This randomized trial found no significant difference in bleeding or thromboembolic events between triple therapy (adding cilostazol) and modified dual therapy (switching to low-dose prasugrel) over 90 days. Clinicians may consider either regimen for HTPR patients, but the choice remains individualized based on patient factors and cost.
Practice change
Confirms current practice: either triple therapy or switching to low-dose prasugrel are reasonable options for HTPR patients.
More context
Key details
- Prospective, randomized trial comparing triple antiplatelet therapy (aspirin, clopidogrel, cilostazol) vs modified dual antiplatelet therapy (aspirin, low-dose prasugrel) in HTPR patients.
- 172 of 198 participants maintained initial therapy for 90 days.
High-yield
No significant difference in bleeding or thromboembolic events between triple antiplatelet therapy and modified dual antiplatelet therapy in HTPR patients undergoing stent-assisted coiling.
Clinical context
High on-treatment platelet reactivity (HTPR) is associated with increased thromboembolic risk in neurointerventional procedures. Modified antiplatelet strategies have been proposed but comparative data are limited.
Limitations
Single-center design may limit generalizability.Short follow-up of 90 days; longer-term outcomes unknown.
Methodological critique
Open-label design may introduce bias, but objective outcomes (bleeding, thromboembolic events) mitigate this.
Teaching pearl
When managing HTPR in neurointerventional patients, remember that both adding cilostazol and switching to low-dose prasugrel are viable options; monitor PRU values to guide therapy, as prasugrel may achieve greater platelet inhibition.
Funding and COI
Not stated
Tumor / Skull Base
Improved coping and self-efficacy drive improvements in mood among caregivers of patients with primary malignant brain tumors: Results from a randomized controlled trial.
Research • Tumor / Skull Base • Neuro-oncology • 2026-07-01
For caregivers of PMBT patients with anxiety, interventions like NeuroCARE that enhance coping and self-efficacy can effectively reduce distress.
Study snapshot
Design
Randomized controlled trial (secondary analysis)
Population
Caregivers of patients with primary malignant brain tumors (PMBT) with clinically significant anxiety
Intervention
NeuroCARE (6-session telehealth behavioral intervention)
Comparator
Usual care
Primary outcome
Anxiety and depression symptoms at 11 weeks (HADS)
Why it matters
Caregivers of patients with primary malignant brain tumors (PMBT) experience high rates of anxiety and depression. This secondary analysis of a randomized trial found that improvements in coping and self-efficacy mediated the positive effects of the NeuroCARE intervention on caregiver mood. Clinicians should consider interventions that target coping and self-efficacy to reduce distress in PMBT caregivers.
Practice change
May support use of interventions targeting coping and self-efficacy to improve caregiver mood.
More context
Key details
- Secondary analysis of a randomized controlled trial (N=120) of NeuroCARE, a 6-session telehealth intervention for PMBT caregivers.
- Mediation analysis showed that changes in coping and self-efficacy from baseline to 11 weeks mediated improvements in anxiety and depression.
- NeuroCARE includes psychoeducation, cognitive-behavioral strategies, mindfulness, and acceptance-based techniques.
- Caregivers were required to have clinically significant anxiety (GAD-7 ≥5) at baseline.
- Results suggest coping and self-efficacy are active ingredients of the intervention.
High-yield
Improved coping and self-efficacy mediated the effect of NeuroCARE on reducing anxiety and depression in PMBT caregivers.
Clinical context
Caregivers of PMBT patients experience high rates of anxiety and depression. Behavioral interventions are needed to address this distress.
Limitations
Secondary analysis; not powered for mediation.Single-site study may limit generalizability.
Methodological critique
Mediation analysis is exploratory; causal inference limited by lack of blinding.
Teaching pearl
When supporting caregivers, focus on building coping skills and self-efficacy; these are key mechanisms that drive improvements in mood.
Funding and COI
Not stated
Spine
Posterior lumbar facet arthroplasty versus fusion for the treatment of spondylolisthesis: 3-year results from the Total Posterior Spine System investigational device exemption study.
Research • Spine • Neurosurgical focus • 2026-07-01
Preliminary evidence; confirm full-text methods and endpoints before changing practice.
Why it matters
Policy and payment trends can influence procedure selection, access to care, and practice sustainability in spine surgery.
High-yield
Randomized trial, N=321; intention-to-treat analysis in results; adverse events in safety tables.
Functional
The deep brain stimulation response network in Parkinson's disease operates in the high beta band.
Research • Functional • Brain : a journal of neurology • 2026-07-07
For Parkinson's disease patients undergoing STN-DBS, optimizing stimulation to enhance high beta band cortico-subthalamic coupling may improve motor outcomes.
Study snapshot
Design
Multicenter cohort study
Population
Parkinson's disease patients undergoing subthalamic DBS (n=100 hemispheres)
Intervention
Analysis of cortico-subthalamic coupling in high beta band
Comparator
Theta-alpha and low beta coupling
Primary outcome
Association of cortico-subthalamic coupling with clinical DBS outcomes
Why it matters
Before this study, DBS response networks were characterized spatially using fMRI, but the temporal dynamics of neural activity were not integrated. This study adds that the DBS response network operates specifically in the high beta band, with cortico-subthalamic coupling in this frequency explaining clinical outcomes. Clinicians may consider that optimal DBS outcomes are associated with high beta connectivity, potentially guiding stimulation parameter adjustments.
Practice change
Confirms current practice; may support using high beta band as a biomarker for DBS programming.
More context
Key details
- Subthalamic local field potentials and whole-brain MEG recorded concurrently in 100 hemispheres.
- Cortico-subthalamic coupling correlated with stimulation outcomes at every cortical vertex.
- High beta coupling map spatially resembled fMRI-based network (R=0.40, p=0.039).
- Optimal map predicted outcomes across DBS centers (R=0.74, p=8.9×10^-5).
- Maximal connectivity to this network associated with optimal DBS outcomes.
High-yield
High beta band cortico-subthalamic coupling (βstd=0.30, p=0.002) predicts DBS outcomes, while theta-alpha and low beta do not.
Clinical context
DBS of the subthalamic nucleus improves motor symptoms in Parkinson's disease. Optimal DBS response networks have been characterized using fMRI, but neural activity is faster than fMRI resolution.
Limitations
Observational cohort design limits causal inference.Generalizability may be limited by multicenter but non-randomized sampling.
Methodological critique
Concurrent MEG-LFP recordings provide high spatiotemporal resolution, but causality not established.
Teaching pearl
When programming DBS, consider that high beta frequency (around 20-30 Hz) cortico-subthalamic connectivity may be a biomarker for optimal response, not just spatial targeting.
Funding and COI
Not stated
General Neurosurgery
Hyperdense Capsule Sign at Noncontrast CT as an Indication for Middle Meningeal Artery Embolization for Nonacute Subdural Hematomas: A MAGIC-MT Trial Post Hoc Analysis.
Research • General Neurosurgery • Radiology • 2026-07
For patients with nonacute SDH and hyperdense capsule sign on CT, consider adjunctive MMAE to reduce recurrence and adverse events.
Study snapshot
Design
Post hoc analysis of randomized controlled trial (MAGIC-MT)
Population
697 participants with nonacute SDH (median age 69, 575 male)
Intervention
Middle meningeal artery embolization (MMAE) plus usual care
Comparator
Usual care alone
Primary outcome
Symptomatic recurrence or progression of SDH
Why it matters
Before this study, indications for middle meningeal artery embolization (MMAE) in nonacute subdural hematoma (SDH) were unclear. This post hoc analysis of the MAGIC-MT trial found that the hyperdense capsule sign (HDCS) on noncontrast CT identifies patients who benefit from MMAE, with lower recurrence/progression (5.0% vs 12.0%, p=0.009) and fewer serious adverse events (5.9% vs 15.1%, p=0.002). Clinicians should consider HDCS presence when selecting candidates for MMAE.
Practice change
May support using HDCS on noncontrast CT to select patients for MMAE.
More context
Key details
- Post hoc analysis of MAGIC-MT RCT comparing adjunctive MMAE vs usual care.
High-yield
See source article for primary outcome data.
Clinical context
Hematoma recurrence and progression remain common in nonacute SDH. Indications for MMAE are limited.
Limitations
Post hoc analysis with potential for unmeasured confounders.Single RCT data; validation in independent cohorts needed.
Methodological critique
Post hoc analysis may introduce bias; results require prospective validation.
Teaching pearl
Look for the hyperdense capsule sign on noncontrast CT—a hyperdense rim around the SDH—as it may predict benefit from MMAE.
Funding and COI
Not stated
Basic Science
Rapid In Vitro Pathological Diagnosis of Glioma Using Dual-Color Quantum Dot Probes for Precise Intraoperative Resection.
Research • Basic Science • Advanced science (Weinheim, Baden-Wurttemberg, Germany) • 2026-07-06
Preclinical evidence; no immediate practice change pending clinical validation.
Study snapshot
Design
Basic science (preclinical)
Population
Not specified (preclinical study using cell lines and tissue samples)
Intervention
Dual-color quantum dot probes (green CTX and blue IDH1) for frozen section immunofluorescence
Comparator
None (single-arm probe development and validation)
Primary outcome
Specificity and sensitivity of probe labeling for glioma cells and IDH1 mutation
Why it matters
Before this study, intraoperative identification of glioma boundaries and IDH1 mutation status required separate, time-consuming techniques unsuitable for real-time surgical guidance. This study introduces dual-color quantum dot probes that simultaneously label glioma cells (green) and IDH1 mutations (blue) on frozen sections, enabling rapid in vitro pathological diagnosis. Clinicians could consider using this probe system to tailor resection extent based on IDH1 status, potentially improving functional preservation in IDH-mutant gliomas while maximizing resection in wild-type tumors.
Practice change
Does not change current clinical practice but may inform future translational work.
More context
Key details
- Developed blue (IDH1) and green (CTX) perovskite quantum dot probes for dual-color staining of glioma frozen sections.
- Probes use PLGA coating for water/oxygen stability and charge coupling for antibody conjugation.
- Green CTX probe targets chloride channels on glioma cell membranes; blue IDH1 probe targets cytoplasmic IDH1 mutations.
- TCGA/CGGA analysis confirmed IDH1 mutation as independent protective factor (HR=0.32) and predictor of chemosensitivity.
- Probes enable rapid intraoperative pathological diagnosis to guide resection strategy based on IDH1 status.
- IDH1-mutant gliomas may benefit from function-preserving resection; wild-type require maximal resection.
High-yield
See source article for primary outcome data.
Clinical context
Gliomas are infiltrative tumors where complete resection is challenging. IDH mutation status influences prognosis and treatment response, but current intraoperative methods cannot simultaneously assess boundaries and molecular subtype.
Limitations
Preclinical study without in vivo or clinical validation of probe performance during actual surgery.Sample size and patient data for probe testing not reported; generalizability to diverse glioma subtypes unconfirmed.
Methodological critique
Preclinical study without in vivo or clinical validation; probe performance in real surgical settings remains unknown.
Teaching pearl
When considering extent of resection for gliomas in eloquent areas, remember that IDH1-mutant tumors are more chemosensitive and radiosensitive, supporting a more conservative resection to preserve function, whereas IDH1-wild-type tumors require maximal safe resection due to aggressive behavior.
Funding and COI
Not stated
Trials to Know
International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)
Trial • Trials to Know • ClinicalTrials.gov • 2026-07-12
Why it matters
This large international registry will collect real-world outcomes on the use of intra-arterial and endosaccular flow diverters for intracranial aneurysms. For neurosurgeons, it provides critical data on device performance, complication rates, and long-term efficacy across diverse populations, helping to refine treatment algorithms for both ruptured and unruptured aneurysms.
Lidocaine Infusion for Headache After Subarachnoid Hemorrhage
Trial • Trials to Know • ClinicalTrials.gov • 2026-07-12
Why it matters
This trial investigates lidocaine infusion as a treatment for refractory headaches following nontraumatic subarachnoid hemorrhage, a common complication with limited evidence-based therapies. If effective, it could provide a non-opioid option for pain management in this neurosurgical population.
CAPTURE AMI: Mechanical Aspiration Thrombectomy vs. No Thrombus Modification in STEMI
Trial • Trials to Know • ClinicalTrials.gov • 2026-07-12
Why it matters
This trial evaluates sustained mechanical aspiration thrombectomy prior to PCI in STEMI patients with high thrombus burden, a scenario where optimal management remains debated. If effective, it could reduce distal embolization and improve myocardial reperfusion, directly impacting neurosurgical patients who may require antiplatelet therapy for concomitant coronary disease.
More context
Key details
- Phase 2/3, recruiting
From the Preprint Wire
Computational model of CA1 theta-gamma oscillations under DBS: mechanistic insights for memory disorders
Preprint • From the Preprint Wire • biorxiv • 2026-06-28
Why it matters
This unreviewed preprint presents a computationally efficient model of hippocampal CA1 theta-gamma oscillations, which are critical for memory. For neurosurgeons exploring DBS for Alzheimer's disease, it offers a framework to understand how stimulation parameters and electrode placement affect neural dynamics, potentially guiding future clinical protocols.
More context
Key details
- Reduced multicompartment model of CA1 includes pyramidal, basket, and OLM cells with simplified morphologies and CA3-to-CA1 axonal projections.
- Model reproduces theta-nested gamma oscillations characteristic of healthy memory-related activity.
- Systematic testing of electrode placement, orientation, amplitude, and frequency reveals that afferent pathway recruitment is key to modulating CA1 dynamics.
Multimodal characterization of variation in neuronal types in the mouse basal ganglia
Preprint • From the Preprint Wire • biorxiv • 2026-06-28
Why it matters
This unreviewed preprint provides a comprehensive multimodal analysis of over 900 neurons in the mouse basal ganglia, linking gene expression, physiology, and morphology. For neurosurgeons, understanding the cellular diversity and topographic organization of the basal ganglia is crucial for refining deep brain stimulation targets and interpreting circuit dysfunction in movement disorders.
More context
Key details
- Patch-seq experiments on >900 neurons from mouse basal ganglia slices integrated transcriptomics, electrophysiology, and morphology.
- MSN gradient along dorsolateral-ventromedial axis corresponds to differences in action potential kinetics and dendritic complexity.
- Comparison with macaque data suggests conservation of the transcriptomic-spatial-physiological relationship across species.
- Striatal interneurons show variation consistent with the MSN gradient, and multimodal data from globus pallidus, subthalamic nucleus, and substantia nigra link transcriptomic types to prior descriptions.
- The transcriptomic gradient is better preserved in globus pallidus externa and interna than in substantia nigra pars reticulata.